Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0T3LF
|
|||
| Former ID |
DAP000572
|
|||
| Drug Name |
Dextroamphetamine
|
|||
| Synonyms |
D-Amphetamine; dextroamphetamine; Dexamphetamine; Dexamfetamine; (S)-Amphetamine; Dexadrine; (+)-(S)-Amphetamine; Dexedrine; (2S)-1-phenylpropan-2-amine; (S)-(+)-Amphetamine; Dextrostat; Desamfetamina; (S)-1-Phenyl-2-propylamine; Dexidrine; Sympamin; Dephadren; Amsustain; (+)-Phenaminum; (+)-alpha-Methylphenethylamine; (S)-1-Phenyl-2-aminopropane; (+)-alpha-Methylphenylethylamine; D-(S)-Amphetamine; (S)-(+)-beta-Phenylisopropylamine; 51-64-9; (S)-alpha-Phenylethylamine; (2S)-(+)-Amphetamine; Benzedrine; Dexacaps; Dexamfetamina; Dexamfetaminum; Dexamphetaminum; Dexanfetamina; Isoamycin; Propisamine; Psychedrine; Raphetamine; Rhinalator; Simpatedrin; Sympamine; Sympatedrine; Weckamine; Desamfetamina [DCIT]; Dexedrine Spansule; Dextroamphetamine [USAN]; Dextroamphetamine resin complex; D-AM; Dexamfetamina [INN-Spanish]; Dexamfetamine (INN); Dexamfetaminum [INN-Latin]; Dexamphetaminum [INN-Latin]; Dexanfetamina [INN-Spanish]; Dexedrine (TN); Dextro-Amphetamine; Dextro-Amphetamine Sulfate; Dextroamphetamine (USAN); Dextrostat (TN); Dl-Amphetamine; Dl-Benzedrine; Fenylo-izopropylaminyl; Beta-phenyl-isopropylamine; D-alpha-methylphenethylamine; Alpha-Methylphenethylamine, d-form; S(+)-Amphetamine; D-(+)-Amphetamine; D-1-Phenyl-2-aminopropan; D-1-Phenyl-2-aminopropan [German]; D-1-Phenyl-2-aminopropane; D-2-Amino-1-phenylpropane; Dl-1-Phenyl-2-aminopropane; Benzeneethanamine, alpha-methyl-, (aS)-(9CI); Phenethylamine, alpha-methyl-, (+)-(8CI); (+/-)-Benzedrine; (+/-)-Desoxynorephedrine; (+/-)-beta-Phenylisopropylamine; (S)-1-Phenyl-2-propanamine; (S)-alpha-Methylphenethylamine; (S)-alpha-methylbenzeneethanamine; (alphaS)-alpha-methylbenzeneethanamine; dextroamphetamine sulfate (oral liquid, ADHD), Auriga
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] | Approved | [1] | |
| Narcolepsy [ICD-11: 7A20; ICD-10: G47.4] | Approved | [1] | ||
| Therapeutic Class |
Central Nervous System Stimulants
|
|||
| Company |
GlaxoSmithKline
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C9H13N
|
|||
| Canonical SMILES |
CC(CC1=CC=CC=C1)N
|
|||
| InChI |
1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3/t8-/m0/s1
|
|||
| InChIKey |
KWTSXDURSIMDCE-QMMMGPOBSA-N
|
|||
| CAS Number |
CAS 51-64-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10086, 841177, 8153594, 10318924, 15170721, 17397829, 29224859, 30896359, 46506252, 47359952, 47954515, 48415867, 50004613, 50071310, 50113060, 57322985, 77830612, 96099848, 103185157, 103933285, 104310370, 127272464, 127272465, 127329738, 127329739, 127329740, 127329741, 127329742, 127329743, 127329744, 127329745, 127329746, 128273812, 128445969, 134337863, 134338391, 134338667, 134972590, 135650979, 137001216, 142361370, 160963530, 170475110, 170506196, 175266841, 175269378, 175444077, 179116645, 184585369, 223826584
|
|||
| ChEBI ID |
CHEBI:4469
|
|||
| ADReCS Drug ID | BADD_D00636 ; BADD_D00637 | |||
| SuperDrug ATC ID |
N06BA02
|
|||
| SuperDrug CAS ID |
cas=000051649
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Trace amine-associated receptor-1 (TAAR1) | Target Info | Modulator | [2], [3], [4], [5] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | G alpha (s) signalling events | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes. Neuropharmacology. 2014 Oct;85:499-507. | |||
| REF 3 | Alpha-1B adrenergic receptor knockout mice are protected against methamphetamine toxicity. J Neurochem. 2003 Jul;86(2):413-21. | |||
| REF 4 | Involvement of the alpha(1D)-adrenergic receptor in methamphetamine-induced hyperthermia and neurotoxicity in rats. Neurotox Res. 2013 Aug;24(2):130-8. | |||
| REF 5 | Methamphetamine increases the hippocampal alpha(2A)-adrenergic receptor and Galpha(o) in mice. Neurosci Lett. 2002 Dec 16;334(3):145-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.